Hernia Abd Wall Recons - BDE vs Exparel

Conditions

• BDE for Hernia Patients
• Exparel for Hernia Patients

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• BDE Injectable Drug — DRUG
  Bupivacaine, Dexamethasone, Epinephrine for hernia patients receiving abdominal wall reconstruction
• Exparel Injectable Drug — DRUG
  Exparel for hernia patients receiving abdominal wall reconstruction

Study Details

This trial compares how two different numbing medications help patients feel the least amount of pain while recovering from surgery.

Key Dates

Start date

Jan 13, 2026

Status verified

Mar 2026

Primary completion

Nov 12, 2029

Completion

Nov 12, 2029

Study Design

Enrollment

128 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: BDE for hernia patients
  112.5 mg of bupivacaine, 3mg dexamethasone and 0.15 mg of epinephrine. In a 30mL syringe. This will be administered into the transversus abdominis plane on both sides.
• Active Comparator: Exparel for hernia patients
  266mg (20ml) mixed with 30 mls of 0.25% marcaine, administered via syringe in the transversus abdominis plane on both sides.

Primary Outcome Measure

Morphine Milligram Equivalent [ Time Frame: Post-Op day 1, 2, 3, 4 and 2 Week Follow-up (Day 14) ]

Locations (1)

Find similar trials in Dallas, TX